Gazyva Achieves Key Milestone in Phase III Trial for Nephrotic Syndrome

Genentechs Gazyva (obinutuzumab) demonstrates promising results in a Phase III trial for idiopathic nephrotic syndrome, raising hopes for a potential cure in affected children and young adults.

• The Phase III INShore study showed that Gazyva (obinutuzumab) led to a higher rate of sustained complete remission at one year compared to mycophenolate mofetil in patients aged 2 to 25.
• In this clinical trial, participants with idiopathic disease experienced significant improvements, suggesting Gazyva as a more effective option for managing nephrotic syndrome and minimizing relapse risks.
• The results indicate that Gazyva may provide an alternative treatment with fewer side effects than mycophenolic acid, potentially transforming the standard care for nephrotic syndrome.